Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Plant Virus Infection Immunity and Control
share announcement

Plant Virus Infection Immunity and Control

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (18 October 2022) | Viewed by 8151

Special Issue Editor

Dr. Kathleen Hefferon

E-Mail Website1 Website2
Guest Editor
Department of Cell and Systems Biology, Cornell University, Ithaca, NY 14850, USA
Interests: plant biotechnology; transgenic plant vaccine; plant virus nanoparticles for anti-cancer therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A significant challenge in cancer treatment is improving health outcomes by specifically targeting biologics to tumor cells. Plant virus-based nanotechnology holds great promise for this as well as other applications, such as cancer vaccine production. Plant viruses are biodegradable and easy to produce and have no cold chain requirements. Plant viruses also naturally occur in a diversity of shapes and sizes and are nontoxic to mammalian cells. Several different plant virus capsid proteins (CP) are known to elicit immune responses. For this reason, plant viruses have found a niche in the future of medical research and development. This Special Issue thus serves to focus on the great utility of plant viruses for therapeutic applications.

Dr. Kathleen Hefferon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • plant virus
  • virus-based
  • cancer treatment
  • nanotechnology
  • immune
  • biologics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 580 KiB  
Review
Recent Progress on Vaccines Produced in Transgenic Plants
by Goabaone Gaobotse, Srividhya Venkataraman, Kamogelo M. Mmereke, Khaled Moustafa, Kathleen Hefferon and Abdullah Makhzoum
Vaccines 2022, 10(11), 1861; https://doi.org/10.3390/vaccines10111861 - 03 Nov 2022
Cited by 4 | Viewed by 5578
Abstract
The development of vaccines from plants has been going on for over two decades now. Vaccine production in plants requires time and a lot of effort. Despite global efforts in plant-made vaccine development, there are still challenges that hinder the realization of the [...] Read more.
The development of vaccines from plants has been going on for over two decades now. Vaccine production in plants requires time and a lot of effort. Despite global efforts in plant-made vaccine development, there are still challenges that hinder the realization of the final objective of manufacturing approved and safe products. Despite delays in the commercialization of plant-made vaccines, there are some human vaccines that are in clinical trials. The novel coronavirus (SARS-CoV-2) and its resultant disease, coronavirus disease 2019 (COVID-19), have reminded the global scientific community of the importance of vaccines. Plant-made vaccines could not be more important in tackling such unexpected pandemics as COVID-19. In this review, we explore current progress in the development of vaccines manufactured in transgenic plants for different human diseases over the past 5 years. However, we first explore the different host species and plant expression systems during recombinant protein production, including their shortcomings and benefits. Lastly, we address the optimization of existing plant-dependent vaccine production protocols that are aimed at improving the recovery and purification of these recombinant proteins. Full article
(This article belongs to the Special Issue Plant Virus Infection Immunity and Control)
►▼ Show Figures

Figure 1

16 pages, 1692 KiB  
Review
Multifunctional Plant Virus Nanoparticles for Targeting Breast Cancer Tumors
by Mehdi Shahgolzari, Hassan Dianat-Moghadam, Afagh Yavari, Steven N. Fiering and Kathleen Hefferon
Vaccines 2022, 10(9), 1431; https://doi.org/10.3390/vaccines10091431 - 30 Aug 2022
Cited by 7 | Viewed by 2230
Abstract
Breast cancer treatment using plant-virus-based nanoparticles (PVNPs) has achieved considerable success in preclinical studies. PVNP-based breast cancer therapies include non-targeted and targeted nanoplatforms for delivery of anticancer therapeutic chemo and immune agents and cancer vaccines for activation of local and systemic antitumor immunity. [...] Read more.
Breast cancer treatment using plant-virus-based nanoparticles (PVNPs) has achieved considerable success in preclinical studies. PVNP-based breast cancer therapies include non-targeted and targeted nanoplatforms for delivery of anticancer therapeutic chemo and immune agents and cancer vaccines for activation of local and systemic antitumor immunity. Interestingly, PVNP platforms combined with other tumor immunotherapeutic options and other modalities of oncotherapy can improve tumor efficacy treatment. These applications can be achieved by encapsulation of a wide range of active ingredients and conjugating ligands for targeting immune and tumor cells. This review presents the current breast cancer treatments based on PVNP platforms. Full article
(This article belongs to the Special Issue Plant Virus Infection Immunity and Control)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop